Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Explorative pharmacogenomic study of everolimus adverse effects in renal transplant recipients
2015-004459-38Phase 4Terminated
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of everolimus in Kidney allograft status (RTx), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoint: Primary transcriptomic endpoint. Started Jan 2021; status: terminated.
02
Drugs
everolimus
03
Conditions
Kidney allograft status (RTx)
Beyond the preview
Go deeper on 2015-004459-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004459-38.